TIL (tumor infiltrating lymphocytes) and interleukin 2 versus abstention as adjuvant treatment in melanoma with only one invaded lymphnode after lymphnodes excision.

Trial Profile

TIL (tumor infiltrating lymphocytes) and interleukin 2 versus abstention as adjuvant treatment in melanoma with only one invaded lymphnode after lymphnodes excision.

Completed
Phase of Trial: Phase III

Latest Information Update: 30 Jan 2013

At a glance

  • Drugs Interleukin-2 (Primary) ; Tumour infiltrating lymphocytes (Primary)
  • Indications Malignant melanoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Dec 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 30 Jun 2008 The expected completion date for this trial is now 1 Jun 2011 as reported by ClinicalTrials.gov.
    • 22 Oct 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top